Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
An analysis of individual participant data from the VICTORIA and VICTOR trials has been conducted to examine the use of vericiguat in patients with heart failure and reduced ejection fraction. The analysis appears to have considered patients across the risk spectrum. The results of this analysis are being reported, although the specific findings are not detailed in the available information.